Empirical Antibiotic Guidelines for the Management of Common Infections in Adult Inpatients

Total Page:16

File Type:pdf, Size:1020Kb

Empirical Antibiotic Guidelines for the Management of Common Infections in Adult Inpatients EMPIRICAL ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMON INFECTIONS IN ADULT INPATIENTS Useful contacts: Consultant Clinical Microbiologist via switchboard Antimicrobial Pharmacist Bleep 294 Medicines Information Ext 2092 Topic/ Heading: Empirical antibiotic guideline for the management of common infections in adult inpatients Lead Clinician for Guideline: Dr. S N Patel, Consultant Microbiologist & Nicola Robinson, Senior Pharmacist Antimicrobials/ ICU Discipline: Medicines Management / Microbiology / Pharmacy Date of Guideline: September 2017 Version: 4.0 Approved By: Drugs & Therapeutics Committee and Antibiotic Stewardship Group Date: 26/7/16 Audit Date: Monthly and as indicated in annual antibiotic audit plan Guideline Review Date: September 2018 Review Completed By: Dr. S N Patel Consultant Microbiologist, Emma Guthrie Senior Pharmacist, Agnieszka Fryer Senior Pharmacist. Rationale for Development: To support prudent use of antimicrobials across the Trust Aims and Objectives: To ensure appropriate antibiotic treatment of common infections in adult inpatients Method of Guideline Development: In accordance with Trust policy Equality Impact Assessment: n/a Roles & Responsibilities: refer to Antimicrobial Prescribing policy in PIMS Guideline: Empirical antibiotic guidelines for the management of common infections in adult inpatients Evidence Base: See reference list Consultation: 2013 Blue Book with changes approved by relevant clinicians Implementation: Available via PIMS Monitoring: Antibiotic Stewardship Group annual audit plan Training Plan: Incorporated into induction training of new doctors and into regular training of medical, pharmacy and nursing staff. Outcome Measures and Audit Criteria: Regular antibiotic audits in medicine and surgery and antibiotic ward rounds Assessment of Competence to Carry Out the Procedure n/a Author: Dr Sneha Patel, Consultant Microbiologist & Emma Guthrie, Senior Pharmacist and Agnieszka Fryer, Senior Pharmacist Empirical antibiotic guidelines for the management of common infections in adult inpatients Version 4.2 Review Date: September 2018 Page 1 of 57 CONTENTS 1 INTRODUCTION .................................................................................................................................................. 3 2 RECOMMENDATIONS FOR THE PRUDENT USE OF ANTIMICROBIALS .................................................................. 4 2.1 PRINCIPLES OF GOOD ANTIBIOTIC PRESCRIBING ............................................................................................................ 4 2.2 REDUCING/PREVENTING C.DIFFICILE INFECTIONS ......................................................................................................... 5 2.3 IV TO ORAL SWITCH GUIDANCE ............................................................................................................................... 5 2.4 CLINICAL ADVICE ................................................................................................................................................... 5 2.5 RESTRICTED ANTIBIOTICS ......................................................................................................................................... 5 2.6 PENICILLIN ALLERGY OR NOT? ................................................................................................................................. 6 2.7 SPECIMENS .......................................................................................................................................................... 6 3 BONE AND JOINT INFECTIONS ............................................................................................................................ 7 4 CARDIOVASCULAR SYSTEM INFECTIONS ............................................................................................................ 8 4.1 BACTERIAL ENDOCARDITIS – EMPIRICAL THERAPY ........................................................................................................ 8 4.2 BACTERIAL ENDOCARDITIS – ORGANISM KNOWN......................................................................................................... 9 5 CENTRAL NERVOUS SYSTEM INFECTIONS ......................................................................................................... 11 5.1 BACTERIAL MENINGITIS ........................................................................................................................................ 11 5.2 OTHER CNS INFECTIONS....................................................................................................................................... 12 5.3 PROPHYLAXIS FOR CONTACTS OF HAEMOPHILUS AND MENINGOCOCCUS MENINGITIS ...................................................... 13 6 GASTROINTESTINAL INFECTIONS (INCLUDING CLOSTRIDIUM DIFFICILE INFECTION) ......................................... 14 6.1 GASTROINTESTINAL INFECTIONS ............................................................................................................................. 14 6.2 CLOSTRIDIUM DIFFICILE INFECTION (CDI) ................................................................................................................. 16 7 RESPIRATORY SYSTEM INFECTIONS .................................................................................................................. 18 8 SEPSIS............................................................................................................................................................... 22 9 SKIN AND SOFT TISSUE INFECTIONS ................................................................................................................. 23 10 UROGENITAL INFECTIONS ................................................................................................................................ 24 APPENDIX A – THERAPEUTIC DRUG MONITORING (TDM) ......................................................................................... 27 A.1 ONCE DAILY GENTAMICIN PROTOCOL ..................................................................................................................... 28 A.2 LOW DOSE GENTAMICIN FOR BACTERIAL ENDOCARDITIS ............................................................................................. 30 A.3 ROLES AND RESPONSIBILITIES FOR GENTAMICIN PRESCRIBING AND MONITORING ............................................................ 31 A.4 AMIKACIN .......................................................................................................................................................... 32 A.5 VANCOMYCIN ..................................................................................................................................................... 33 A.6 TEICOPLANIN ...................................................................................................................................................... 35 APPENDIX B – SURGICAL ANTIBIOTIC PROPHYLAXIS ................................................................................................. 36 APPENDIX C – SPLENECTOMY PATIENTS: PREVENTION OF INFECTION ...................................................................... 42 APPENDIX D – NEUTROPENIA: MANAGEMENT OF NEUTROPENIC FEVER ................................................................. 44 APPENDIX E – DIABETIC FOOT INFECTION ................................................................................................................. 47 APPENDIX F – SPECTRUM OF ACTIVITY OF ANTIBIOTICS ........................................................................................... 49 APPENDIX G – DOSE ADJUSTMENT IN RENAL IMPAIRMENT ..................................................................................... 52 Author: Dr Sneha Patel, Consultant Microbiologist & Emma Guthrie, Senior Pharmacist and Agnieszka Fryer, Senior Pharmacist Empirical antibiotic guidelines for the management of common infections in adult inpatients Version 4.0 Review Date: August 2018 Page 2 of 57 1 Introduction All NHS bodies are legally responsible for having antimicrobial prescribing policies in place as summarised in the following publications from the Department of Health (DH): The Health and Social Care Act, Code of Practice for health and adult social care on the prevention and control of infections and related guidance. 2008 (Updated 2010.); The Health Act 2006 Code of Practice for the Prevention and Control of Healthcare Associated Infections. The DH issued specific recommendations in the supporting document, Saving Lives: reducing infection, delivering clean and safe care: Antimicrobial Prescribing, including regular audit of antimicrobial prescribing to determine compliance with local guidelines. Further guidance provided an outline of evidence based antimicrobial stewardship in the secondary care setting: Antimicrobial Stewardship ‘Start Smart - then Focus’ DH November 2011(updated 2015). The purpose of empirical antibiotic guidelines is to: Guide prescribers on the use of antibiotics in an evidence-based manner. Reduce the incidence of Healthcare Associated Infections (HCAIs) Reduce the emergence of antimicrobial resistance Minimise adverse effects Make the Trust compliant with the Health and Social Care Act. This guideline is not all encompassing. It aims to include the common infections seen at Kingston Hospital. This guideline is adapted from the Blue Book Guideline for the Management of Common Medical Emergencies and for the use of Antimicrobial Drugs 2013 edition and revised. Every attempt has
Recommended publications
  • A Review of Undulant Fever : Particularly As to Its Incidence, Origin and Source of Infection
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1938 A Review of undulant fever : particularly as to its incidence, origin and source of infection Richard M. Still University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Still, Richard M., "A Review of undulant fever : particularly as to its incidence, origin and source of infection" (1938). MD Theses. 706. https://digitalcommons.unmc.edu/mdtheses/706 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. ·~· A REVIEW OF UNDULANT FEVER PARTICULARLY AS TO ITS INCIDENCE, ORIGIN AND SOURCE OF INFECTION RICHARD M. STILL SENIOR THESIS PRESENTED TO THE COLLEGE OF MEDICINE, UNIVERSITY OF NEBRASKA, OMAHA, NEBRASKA, 1958 SENIOR THESIS A REVIEW OF UNDULANT FEVER PARTICULARLY AS TO ITS;. INCIDENCE, ORIGIN .AND SOURCE OF INFECTION :trJ.:RODUCTION The motive for this paper is to review the observations, on Undul:ant Fever, of the various authors, as to the comps.rat!ve im- portance of' milk borne infection and infection by direct comtaC't.•.. The answer to this question should be :of some help in the diagnos- is ot Undulant Fever and it should also be of value where - question of the disease as an occupational entity is presented.
    [Show full text]
  • Patterns of Proinflammatory Cytokines and Inhibitors During Typhoid Fever
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library 1306 Patterns of Proinflammatory Cytokines and Inhibitors during Typhoid Fever Monique Keuter, Edi Dharmana, M. Hussein Gasem, University Hospital, Nijmegen. Netherlands; Diponegoro University, Johanna van der Ven-Jongekrijg, Semarang. Indonesia; F. Hoffman-Lakoche, Basel, Switzerland Robert Djokomoeljanto, Wil M. V. Dolmans, Pierre Demacker, Robert Sauerwein, Harald Gallati, and Jos W. M. van der Meer Cytokines and inhibitors in plasma were measured in 44 patients with typhoid fever. Ex vivo production of the cytokines was analyzed in a whole blood culture system with and without lipopolysaccharide (LPS). Acute phase circulating concentrations of cytokines (±SD) were as follows: interleukin (IL)-IP, <140 pg/ml.; tumor necrosis factor-a (TNFa), 130 ± 50 pg/mL; IL-6, 96 ± 131 pg/ml.; and IL-8, 278 ± 293 pg/ml., Circulating inhibitors were elevated in the acute phase: IL-l receptor antagonist (IL-IRA) was 2304 ± 1427 pg/ml, and soluble TNF receptors 55 and 75 were 4973 ± 2644 pgJmL and 22,865 ± 15,143 pgJmL, respectively. LPS­ stimulated production of cytokines was lower during the acute phase than during convalescence (mean values: IL-IP, 2547 vs. 6576 pg/ml.; TNFa, 2609 vs. 6338 pg/rnl.; IL-6, 2416 vs. 7713 pg/ml.), LPS-stimulated production orIL-iRA was higher in the acute than during the convales­ cent phase (5608 vs. 3977 pg/mL). Inhibited production of cytokines during the acute phase may bedue to a switch from a proinflammatory to an antiinflammatory mode. Typhoid fever is caused by the facultative intracellular tibodies to this cytokine are detrimental [11-16], In experi­ gram-negative bacillus Salmonella typhi and occasionally by mental Salmonella typhimurium infection in mice.
    [Show full text]
  • How I Manage the Febrile Returning Traveller*
    Proc. R. Coll. Physicians Edinb. 1998; 28: 24-33 HOW I MANAGE THE FEBRILE RETURNING TRAVELLER* D. Nathwani,† Dundee Teaching Hospitals NHS Trust, DD3 8EA Humanity has but three great enemies: fever, famine and war; of these by far the greatest, by far the most terrible, is fever. Sir William Osler Throughout the centuries, the clinical diagnosis has been made or strongly suggested by the history, the presence of helpful physical findings and the observation of the patient. Like Osler, physicians since antiquity have viewed fever, an important clinical finding, as an entity worthy of unremitting attention. An eighteenth century English diarist (Fanny Gurney, Celia Book IV, 1782) wrote that ‘travelling is the ruin of all happiness’. Fortunately, this rather gloomy outlook is no longer widely held, as illustrated by the massive increase in public spending on travel and escalation in air travel by UK residents. Between 1991 and 1995 there was a rise to 22.9 million UK residents travelling abroad (International Passenger Survey, Office for National Statistics) and a 12.5 million rise in visitors to the UK over a similar period. Although Spain and France remain the most popular destinations, increasing numbers of British people (approximately three million in 1996) are travelling to the tropics and subtropics. Fever is an important and common presentation of tropical disease and sometimes may be the only manifestation of serious illness. Indeed, 81% of travellers complaining of fever admitted to the Hospital for Tropical Diseases in London, in a period of six months had travelled to the tropics or subtropics (60% sub-Saharan Africa; 13% Indian sub-continent 8% South-East Asia).1 This suggests that both primary and secondary care physicians need to be familiar with the management of patients arriving at, or returning to, this country with a febrile illness.
    [Show full text]
  • Overview of Fever of Unknown Origin in Adult and Paediatric Patients L
    Overview of fever of unknown origin in adult and paediatric patients L. Attard1, M. Tadolini1, D.U. De Rose2, M. Cattalini2 1Infectious Diseases Unit, Department ABSTRACT been proposed, including removing the of Medical and Surgical Sciences, Alma Fever of unknown origin (FUO) can requirement for in-hospital evaluation Mater Studiorum University of Bologna; be caused by a wide group of dis- due to an increased sophistication of 2Paediatric Clinic, University of Brescia eases, and can include both benign outpatient evaluation. Expansion of the and ASST Spedali Civili di Brescia, Italy. and serious conditions. Since the first definition has also been suggested to Luciano Attard, MD definition of FUO in the early 1960s, include sub-categories of FUO. In par- Marina Tadolini, MD Domenico Umberto De Rose, MD several updates to the definition, di- ticular, in 1991 Durak and Street re-de- Marco Cattalini, MD agnostic and therapeutic approaches fined FUO into four categories: classic Please address correspondence to: have been proposed. This review out- FUO; nosocomial FUO; neutropenic Marina Tadolini, MD, lines a case report of an elderly Ital- FUO; and human immunodeficiency Via Massarenti 11, ian male patient with high fever and virus (HIV)-associated FUO, and pro- 40138 Bologna, Italy. migrating arthralgia who underwent posed three outpatient visits and re- E-mail: [email protected] many procedures and treatments before lated investigations as an alternative to Received on November 27, 2017, accepted a final diagnosis of Adult-onset Still’s “1 week of hospitalisation” (5). on December, 7, 2017. disease was achieved. This case report In 1997, Arnow and Flaherty updated Clin Exp Rheumatol 2018; 36 (Suppl.
    [Show full text]
  • Typhoid Fever in a South African In-Patient Population Khan, Mohammad Enayet Hossain
    University of Groningen Typhoid fever in a South African in-patient population Khan, Mohammad Enayet Hossain IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2004 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Khan, M. E. H. (2004). Typhoid fever in a South African in-patient population. [S.n.]. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 27-09-2021 RIJKSUNIVERSITEIT GRONINGEN TYPHOID FEVER IN A SOUTH AFRICAN IN-PATIENT POPULATION Proefschrift ter verkrijging van het doctoraat in de Medische Wetenschappen aan de Rijksuniversiteit Groningen op gezag van de Rector Magnificus, dr. F. Zwarts, in het openbaar te verdedigen op woensdag 10 maart 2004 om 16.15 uur door Mohammad Enayet Hossain Khan geboren op 1 juli 1958 te Dhaka, Bangladesh Promotores: Prof.dr.
    [Show full text]
  • Protracted Simple Continued Fever
    PROTRACTED SIMPLE CONTINUED FEVER. By J. M. Da COSTA, M.D., LL.D., OF PHILADELPHIA. I PROPOSE in this paper to examine into the history and clinical features of fevers of long duration that are not typhoid fever, and to ascertain in how far these continued fevers form a type of their own. Let me first describe, by way of introduction to the subject, a couple of cases of most unusual length: one, seen some years ago from the beginning to the end of the disease, and often since ; the other, a more recent one, investigated repeatedly during its course. Case I.—A number of years ago a young girl was brought to me with very poor digestion and great irritability of the stomach. By strict diet, the use of effervescing mixtures and laxatives, the disorder yielded in ten days, and free bilious discharges, for the most part dark-colored, took place at its end. Shortly afterward an inexplicable fever arose that lasted for three months. The fever was never very high ; it did not, I think, ever exceed 103° F.; it was not ushered in by a chill, nor did chills happen during its continuance. There were, as in any fever, a morning remission and an evening exacerba- tion, but never to a marked degree; theffever was for weeks remarkably regular, only at times and at no stated periods, showing irregularities in its course, and its subsidence and disappearance were as gradual and unmarked by violent changes as its onset. Late in the disease somesweating happened. Beyond the extraordinary fever there was nothing to note; there was no cerebral symptom, save occasional headache; neither nausea nor vomiting; no epistaxis; no diarrhoea, the bowels, indeed, were rather sluggish ; no ab- normal lung or heart condition ; no albumin in the high-colored fever-urine ; no eruption of any kind, not a single, even doubtful, rose-spot.
    [Show full text]
  • The Truth About Drug Fever Committee Met May 17, 2011
    Volume 25, Number 6 June 2011 Drugs & Therapy B N U N L N L N E N T N I N N ADVERSE DRUG REACTIONS FORMULARY UPDATE The Pharmacy and Therapeutics The truth about drug fever Committee met May 17, 2011. 4 products were added in the Formu- t is estimated that about 3–7% of antimicrobials (median 6 days). Cardiac lary; 2 were deleted and designated I febrile episodes are attributed to drug and central nervous system medica- nonformulary and not available. 1 reactions; however, the true incidence is tions can induce fever at a much slower interchange was approved, while 3 unknown due to underreporting and fre- interval, median of 10 and 16 days after criteria for uses were changed. quent misdiagnosis.1 In the hospitalized initiation, respectively. patient, the most common presentation Fever patterns may present as a for drug fever is a patient with a resolv- continuous fever (temperature does not ing infection, on antimicrobial therapy, vary), remittent fever (where tempera- ◆ ADDED and after initial defervescence. Fever in tures vary, but are consistently elevat- Acetaminophen IV this patient can result in the over-utili- ed), intermittent fever (with normal (Ofirmev® by Cadence zation of antimicrobials and the addition temperatures in between), or the most Pharmaceuticals)* of agents to treat an infection that is not common: hectic fever (combination of 4 *Restricted present. This could potentially cause remittent and intermittent). Degree more adverse effects and further contrib- of pyrexia tends to range from 38.8°C Carglumic Acid ute to antimicrobial resistance. (102°F) to 40°C (104°F) but has been ® (Carbaglu by Orphan Europe) One study evaluating 51 episodes reported as high as 42.8°C (109°F).
    [Show full text]
  • Fever in Common Infectious Diseases 5
    Fever in Common Infectious Diseases 5 Core Messages › Infection of the respiratory tract is the most common reason for seeking medical advice and hospital admission in children. A viral upper respiratory tract infec- tion (URTI) is the most common infection of the respiratory tract. › In developing countries, acute respiratory infection remains a leading cause of childhood mortality, causing an estimated 1.5–2 million deaths annually in children younger than 5 years of age. › In developed countries, viruses are responsible for most upper and lower respira- tory tract infections, including pharyngitis and pneumonia. › Although the degree of fever cannot differentiate between viral and bacterial diseases, high fever is associated with a greater incidence of serious bacterial diseases such as pneumonia or meningitis. › Worldwide, diarrheal disease is the leading cause of childhood deaths under 5 years of age. › If the fever does not have an evident source, urinary tract infection (UTI) should be considered, particularly if the fever is greater than 39.0°C and persists for longer than 24–48 h. › Widespread vaccinations against bacteria causing meningitis, such as Hib, and vaccines against meningococci and pneumococci have dramatically reduced the incidence of meningitis. › A child with fever and nonblanching rash should be promptly evaluated to exclude meningococcal diseases. › Young children with malaria may present with irregular fever and not with typi- cal paroxysms of fever, occurring particularly in early falciparum infection or as a consequence of previous chemoprophylaxis, which modifies the typical pattern of fever. A.S. El-Radhi et al. (Eds.) Clinical Manual of Fever in Children. 81 Doi: 10.1007/978-3-540-78598-9, © Springer-Verlag Berlin Heidelberg 2009 82 5 Fever in Common Infectious Diseases 5 5.1 Acute Upper Airway Infection An upper airway infection is the most common infection in children, accounting for half to two-thirds of all childhood infections.
    [Show full text]
  • SLIDE 1 Technical Seminar – Other Causes of Fever This Seminar
    TECHNICAL SEMINAR - OTHER CAUSES OF FEVER SLIDE 1 Technical Seminar – Other Causes of Fever This seminar covers the causes of fever other than malaria. At first glance of the IMCI guidelines, management of fever appears to be restricted to the management of malaria. In reality, the guidelines for managing fever identify most of the common causes of fever. In some countries, other conditions must be considered, but these will be discussed separately. SLIDE 2 & 3 Febrile Illness – Causes Many of the infectious diseases assessed, classified and treated using the IMCI guidelines have fever as a secondary cause. For example, many children with a upper respiratory tract infection, pneumonia or ear infection will have fever. Children with dysentery and diarrhea may also have fever. In these patients, the cause of the fever is treated and fever is not used in decision making. While these conditions all cause fever, the management of the condition itself results in the management of the fever. Hence, no separate guidelines were derived for these conditions. Severe illnesses associated with danger signs are also associated with fever, such as sepsis septicemia and meningitis. The danger signs lead to appropriate referral for the illness. Fever is also associated with malaria, but since there are no other clinical signs that reliably distinguish malaria from other common causes of infection without extensive clinical examination and laboratory testing, the IMCI guidelines concentrate on the management of malaria,. This is discussed in another seminar. SLIDE 4 Febrile Illness – Causes (continued) In other non-obvious causes of fever, the danger signs associated with them would identify a seriously ill child who needs to be referred and managed at the referral facility.
    [Show full text]
  • Uncomplicated Typhoid Fever; Comparison of Azithromycin and Ciprofloxacin in the Treatment
    UNCOMPLICATED TYPHOID FEVER The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-4014 DOI: 10.29309/TPMJ/18.4014 UNCOMPLICATED TYPHOID FEVER; COMPARISON OF AZITHROMYCIN AND CIPROFLOXACIN IN THE TREATMENT Kashif Ali1, Sajid Hussain2, Muhammad Saleem Akhter3, 1. FCPS Assistant Professor Medicine, ABSTRACRT… Objectives: Objectives of this study were To compare the clinical and Ghazi Khan Medical College, bacteriological cure rates of azithromycin and ciprofloxacin in the treatment of uncomplicated Dera Ghazi Khan. typhoid fever and To determine any difference in the clinical and bacteriological cure rates 2. FCPS DHQ / Teaching Hospital, within the two groups of study. Study Design: Quasi experimental study. Setting: Department Dera Ghazi Khan. of Medicine, DHQ/ Teaching Hospital Dera Ghazi Khan. Period: April 2016 to September 2016. 3. FCPS Patients and Methods: A total of 60 patients including both males and females over 18 years Associate Professor Medicine of age were included in the study by Simple random probability sampling. Patients fulfilling the Ghazi Khan Medical College, Dera Ghazi Khan. inclusion criteria were divided in two equal groups of 30 by using the random numbers table. First group was treated with azithromycin one gram on day one and then 500 mg daily for next Correspondence Address: six days. Second group was treated with ciprofloxacin 500mg twice daily for ten days. All the Dr. Kashif Ali Assistant Professor Medicine, data was analyzed by the computer programme SPSS. Frequency, percentages, mean values Ghazi Khan Medical College, and standard deviations were calculated for age, sex, symptoms, signs, culture reports, clinical Dera Ghazi Khan. cure rates and bacteriological cure rates.
    [Show full text]
  • Clinico-Epidemiological Profile and Patterns of Antibiotic Sensitivity Of
    Original research : Clinico-Epidemiological Profile And Patterns Of Antibiotic Sensitivity Of Enteric Fever Cases Among Paediatric Patients In The Adjacent areas of Midnapore - A hospital-based study Tarapada Ghosh *, Souvik Biswas ** , Ranjita Santra (Dhali) *** , Partha Sarathi Satpathi # * Department of Paediatrics, Midnapore Medical College & Hospital, West Midnapore, West Bengal, India., ** Department of Paediatrics, Murshidabad Medical College & Hospital, Murshidabad, West Bengal, India. ***Department of Clinical & Experimental Pharmacology, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India. Department of Microbiology, Midnapore Medical College, West Midnapore, West Bengal, India. Address of the institution: Department of paediatrics and department of Microbiology, Midnapore Medical College & Hospital, West Midnapore, West Bengal, India. Corresponding author: Dr. Souvik Biswas, department of Paediatrics, Midnapore Medical College & Hospital, West Midnapore, West Bengal, India.Email ID: [email protected] Received: June 12, 2018; R eviewed: July 27, 2017; Accepted:September 9, 2017. Citation of article: Tarapada Ghosh, Souvik Biswas, Ranjita Santra (Dhali), Partha Sarathi Satpathi Clinico-Epidemiological Profile And Patterns Of Antibiotic Sensitivity Of Enteric Fever Cases Among Paediatric Patients In The Adjacent areas of Midnapore - A hospital-based study, New Indian Journal of Pediatrics 2018;7(3): p. 137-144 Abstract respectively. Occurrence of S. paratyphi Ainfection and early defervescence was statistically
    [Show full text]
  • Military Medical Research (2020) 7:4
    Jin et al. Military Medical Research (2020) 7:4 https://doi.org/10.1186/s40779-020-0233-6 POSITION ARTICLE AND GUIDELINE Open Access A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Ying-Hui Jin1, Lin Cai2, Zhen-Shun Cheng3, Hong Cheng4, Tong Deng1,5, Yi-Pin Fan6,7, Cheng Fang1, Di Huang1, Lu-Qi Huang6,7, Qiao Huang1, Yong Han2,BoHu8, Fen Hu8, Bing-Hui Li1,5, Yi-Rong Li9, Ke Liang10, Li-Kai Lin2, Li-Sha Luo1, Jing Ma8, Lin-Lu Ma1, Zhi-Yong Peng8, Yun-Bao Pan9, Zhen-Yu Pan11, Xue-Qun Ren5, Hui-Min Sun12, Ying Wang13, Yun-Yun Wang1, Hong Weng1, Chao-Jie Wei3, Dong-Fang Wu4, Jian Xia14, Yong Xiong10, Hai-Bo Xu15, Xiao-Mei Yao16, Yu-Feng Yuan2, Tai-Sheng Ye17, Xiao-Chun Zhang15, Ying-Wen Zhang17, Yin-Gao Zhang2, Hua-Min Zhang6,7, Yan Zhao14, Ming-Juan Zhao1, Hao Zi1,5, Xian-Tao Zeng1,18*, Yong-Yan Wang6,7*, Xing-Huan Wang1,2*, for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM) Abstract In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual.
    [Show full text]